Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alaunos Therapeutics Inc TCRT

Healthcare Biotechnology
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity... see more

Recent & Breaking News (NDAQ:TCRT)

ZIOPHARM Oncology Initiates Phase 2 Study of Ad-RTS IL-12 and Palifosfamide Combination for Treatment of Advanced Breast Cancer

Troy Schwensen March 11, 2013

ZIOPHARM Oncology to Present at the Barclays Global Healthcare Conference

Troy Schwensen March 7, 2013

ZIOPHARM Oncology Announces Initiation of Indiana University-Sponsored Phase 2 Study of Palifosfamide in Recurrent and Incurable Germ Cell (Testicular and Ovarian) Tumors

Troy Schwensen March 6, 2013

Free Research Reports on ARNA, DSCO, MNKD and ZIOP Issued by the Bedford Report

Marketwired February 19, 2013

AVP, LDK, FOLD and ZIOP - Pre-Market Briefing

Marketwired February 14, 2013

FDA Approved a Total of 39 New Drugs in 2012 -- Fifteen Year High

Marketwired February 13, 2013

Free Research Reports on STEM, ZIOP, ATPAQ and GTE Issued by the Bedford Report

Marketwired February 13, 2013

Free Research Report on ZIOPHARM Oncology, Inc., Meritage Homes Corp., NeuStar, Inc., BorgWarner, Inc. and Loral Space & Communications, Inc.

Marketwired February 13, 2013

Phase 3 Trial of ZIOPHARM'S Palifosfamide in First-Line Metastatic Soft Tissue Sarcoma Reaches Target Number of Progression-Free Survival Events

Troy Schwensen February 12, 2013

ZIOPHARM Oncology to Present at the 15th Annual BIO CEO & Investor Conference

Troy Schwensen February 6, 2013

Major Revenue Losses From Patent Expirations Forces Big Pharma Companies to Look to the Biotech Industry for Replacements

Marketwired January 21, 2013

ZIOPHARM Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference

Troy Schwensen January 3, 2013